Background Consider a comparative, randomized clinical study with a specific event time as the primary end point. In the presence of censoring, standard methods of summarizing the treatment difference are based on Kaplan-Meier curves, the logrank test, and the point and interval estimates via Cox's procedure. Moreover, for designing and monitoring the study, one usually utilizes an event-driven scheme to determine the sample sizes and interim analysis time points. Purpose When the proportional hazards (PHs) assumption is violated, the logrank test may not have sufficient power to detect the difference between two event time distributions. The resulting hazard ratio estimate is difficult, if not impossible, to interpret as a treatment contrast. When the event rates are low, the corresponding interval estimate for the 'hazard ratio' can be quite large due to the fact that the interval length depends on the observed numbers of events. This may indicate that there is not enough information for making inferences about the treatment comparison even when there is no difference between two groups. This situation is quite common for a postmarketing safety study. We need an alternative way to quantify the group difference. Methods Instead of quantifying the treatment group difference using the hazard ratio, we consider an easily interpretable and model-free parameter, the integrated survival rate difference over a prespecified time interval, as an alternative. We present the inference procedures for such a treatment contrast. This approach is purely nonparametric and does not need any model assumption such as the PHs. Moreover, when we deal with equivalence or noninferiority studies and the event rates are low, our procedure would provide more information about the treatment difference. We used a cardiovascular trial data set to illustrate our approach. Results The results using the integrated event rate differences have a heuristic interpretation for the treatment difference even when the PHs assumption is not valid. When the event rates are low, for example, for the cardiovascular study discussed in this article, the procedure for the integrated event rate difference provides tight interval estimates in contrast to those based on the event-driven inference method.
Introduction
To assess the relative efficacy or safety of two treatments with an event time as the outcome variable in a comparative clinical trial, one generally uses an expected or estimated number of events over the study time to determine the sample size and monitoring schedule. For interim and final data analyses of such an event-driven trial, we typically summarize the results with a plot of two Kaplan-Meier (KM) curves, S 1 (Á) andŜ 2 (Á); the p-value of the logrank test and the hazard ratio point; and interval estimates [1] . The KM estimates are simply descriptive statistics. The Cox estimate provides a single summary for quantifying the treatment difference. When the proportional hazards (PHs) assumption is nontrivially violated, the interpretation of the treatment contrast from the KM curves can be quite different from that of the aforementioned hazard ratio estimates. In fact, for this situation, the hazard ratio estimate does not have a clear interpretation even in terms of an average hazard ratio over the study time [2, 3] . On the other hand, one may compare two survival functions directly with the differencesD(t) =Ŝ 2 (t) ÀŜ 1 (t) evaluated at a set of specific time points ts or for all t 2 ½t 0 , t 1 a fixed time interval. For instance, comparisons may be made via pointwise or simultaneous confidence interval estimates for the difference of two survival functions over ½t 0 , t 1 [4] . Moreover, one may consider a nonparametric integrated (average) differenceD of fD(t), t 2 ½t 0 , t 1 g as a summary statistic to quantify the treatment contrast, wherê
Such an integrated difference or a weighted version thereof has been proposed as a test statistic for testing the equality of two survival curves, for example, by Pepe and Fleming [5, 6] . They showed that, under a superiority trial setting, this type of test performs well even under the PHs alternative and can be better than the logrank test when the PH assumption is not valid. Under the group sequential testing problem setting, Li [7] and Murray and Tsiatis [8] also showed the advantage of using the average difference of survival rates as a summary of the treatment contrast. Using the weighted KM statistics, other novel testing procedures have been also discussed, for example, by Murray [9] , Shen and Cai [10] , Lee and Chen [11] , Chi [12] , Chi and Su [13] , Chang and Chen [14] , and Lee [15] , and references therein. However, most of the procedures in the literature deal with testing hypothesis. The distributions of the testing statistics are generally derived under the null hypothesis. In this article, we are more interested in the estimation problem, that is, quantifying the size of the treatment difference using the integrated survival rate differenceD or its weighted version. The distribution theory for the estimator is more involved than that in the setting of hypothesis testing.
From the estimation point of view, if the difference of the two survival functions is approximately equal to a constant over ½t 0 , t 1 ,D or its weighted version would consistently estimate such a constant. If the assumption of a constant survival rate difference over ½t 0 , t 1 is not valid, the estimateD still has an intuitive interpretation for the treatment contrast. Furthermore, when we are interested in the treatment difference with respect to relatively long-term survival,D may provide more relevant information than the PH estimate by choosing an appropriate time interval ½t 0 , t 1 . Moreover, when the event rates are low for both groups, the variance estimate of the PH estimator almost entirely depends on the total number of observed events. This generally leads to a conclusion that the trial is futile due to lack of information. That is, at the end of the study, we cannot say whether the two groups are equivalent or one treatment is superior or noninferior to the other.
To illustrate the above point, let us use the data from a clinical trial 'Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE)'. This trial was designed to study whether the angiotensin converting enzyme inhibitors (ACEi) would be effective for reducing certain cardiovascular related events [16] . In this study, 4158 and 4132 patients were randomly assigned to the trandolapril treatment and placebo arms, respectively, and they underwent randomization from November 1996 to June 2000. The median followup time is 4.8 years and the longest is 7 years. For illustration, let the primary event of interest be the Integrated difference of survival rates over time 571 death from all causes and consider a subgroup of patients who are younger than 65 years. Figure 1 gives us the KM curves based on survival data collected at the end of the study from this subgroup of patients (2119 treated and 2085 controls). There are 99 and 94 events in the control and treated arms, respectively. Except for the unstable tail parts, visually there is no difference between the two curves. The PH point estimate and the corresponding 0.95 confidence interval estimate are 0.97 and (0.73, 1.29), respectively. This interval estimate is quite large on the hazard ratio scale, suggesting that there is not enough information about the treatment difference between the ACEi and the placebo. That is, one cannot even claim that the treatment is noninferior to the placebo. Studies with such low event rates are not uncommon, especially when the primary end point is the time to a serious adverse event, for example, in a postmarket safety trial. Using an event-driven approach for designing and analyzing an equivalence or noninferiority trial can be problematic, especially when the observed event rates were lower than their estimated values used at the design stage. On the other hand, using the survival rate differences as the parameters of interest can be quite beneficial for reducing the size and/or the follow-up time of the study. To illustrate this point, in Table 1 , we report the point and 0.95 interval estimates for the differences (ACEi minus placebo) of two KM curves at various study time points ts using the above PEACE data. From a clinical point of view, these intervals are tight. The lengths or precisions of these interval estimates not only depend on the observed number of events but also depend on the numbers of patients in the risk set at each failure time. For example, at month 60, the 0.95 confidence interval for the difference of two survival rates is (21.7, 1.1)%. One may be interested in the average difference of survival functions over the time interval [0, 60] (months) instead of a fixed time point. We show in the next section how to construct confidence intervals based onD: For the present example, the resulting 0.95 confidence interval for this integrated difference is (20.7, 0.6)%. Now, if we are interested in the treatment difference with respect to relatively long-term survival for such a patient population, we may consider an integrated difference over a time interval, for example, [48, 60] . For this case, the resulting interval is (21.4, 1.0)%. These tight confidence intervals for the differences provide valuable information about the lack of efficacy of the ACEi for these relatively young patients.
In the next section, we show how to construct confidence intervals for the integrated difference of two survival functions over a prespecified time interval. A numerical study was conducted to examine the performance of our proposal under various practical settings. Further remarks about the usage of the integrated difference are given in section 'Remarks'.
The distribution of the estimated integrated difference of two survival functions
Let S 1 (Á) and S 2 (Á) be the underlying survival functions forŜ 1 (Á) andŜ 2 (Á), respectively. Let 
where w(Á) is a positive weight function over ½t 0 , t 1 and w = Ð t 1 t 0 w(t)dt. Note that if D(t)s are equal to an unknown constant, say, t, then D w = t. If D(t) is not constant over the time interval, one may choose a weight function w(Á) such that the resulting D w is a meaningful summary of the treatment difference over ½t 0 , t 1 . Now, under the usual random sampling setting, let T ki and C ki be the survival and censoring times for the ith subject in the kth treatment group, respectively, where k = 1, 2, i = 1, . . . , n k . Let U ki = min fT ki , C ki g and D ki = IfT ki C ki g, where I(Á) is the indicator function. Furthermore, let l k (Á) be the hazard function of T ki . Let n = n 1 + n 2 . We assume that p k = lim n!' n k =n . 0 for k = 1, 2. Now, assume that Pr(U ki . t 1 ) . 0, k = 1, 2. Then, using the uniform consistency property of the KM estimator [17] , it is straightforward to show that
consistently estimates D w . To derive an approximation to the distribution ofD w , for t 0 t t 1 we first use the following approximation [18] S k (t) À S k (t)' À S k (t)
where N ki (t) = IfU ki t,
It follows from the martingale central limit theorem [18] that the right-hand side of Equation (3) is asymptotically Gaussian over the interval ½t 0 , t 1 .
Next, using a perturbation-resampling method similar to the wild bootstrap of Lin et al. [19] and Parzen et al. [4] , the distribution of the right-hand side of Equation (3) can be approximated by the conditional distribution (conditional on the data) of
where fZ ki : k = 1, 2, i = 1, . . . , n k g is a random sample from the standard normal, which is independent of the data. It follows that the distribution of (D w À D w ) can be approximated by the conditional distribution of w À1
Note that the only random quantities in Equation (5) are fZ ki g. In practice, to obtain the distribution of Equation (5), we generate a large number M of random samples fZ ki : k = 1, 2, i = 1, . . . , n k g. For each realized normal sample, we compute the corresponding realization of Equation (5) . Then one may use these M realizations of Equation (5) to obtain the sample variance or a robust version thereof as a variance estimate ofD w The corresponding confidence intervals for D w can then be obtained accordingly.
The estimates discussed in the 'Introduction' for the integrated difference of the two survival functions over ½t 0 , t 1 are obtained with w(Á) = 1. When D(t)s are equal to a constant t over ½t 0 , t 1 , we may choose a data-dependent weight function to increase the precision in estimating t: Ifŵ(Á) is uniformly convergent in probability to a deterministic function w(Á) over ½t 0 , t 1 , then
is a consistent estimator for t, where w = Ð t 1 t 0ŵ (t)dt. One possible choice ofŵ(t) is the reciprocal of a variance estimate ofD(t) over the above time interval. In the Appendix, we show that under a more general setting,Dŵ is approximately normal with mean t. Moreover, the above perturbation-resampling method can still be used to approximate the distribution of (Dŵ À t). It is interesting to note that with the same data set from the PEACE study, the 0.95 confidence intervals for t using the reciprocal of the variance estimate as the weight are practically identical to or slightly improved over those reported in Table 1 with the constant weight. For example, for the time interval ½t 0 , t 1 = ½36, 60, the confidence interval with the constant weight is (21.2, 0.9)%. The corresponding empirically weighted one is (21.1, 0.9)%.
When D(t)s vary over ½t 0 , t 1 , the variability of the weight function is not asymptotically ignorable, and the above simple resampling method or the standard martingale central limit theorem may not be used to approximate the distribution of (Dŵ À D w ). It is important to note for this general case, one cannot use the results from Pepe and Fleming [5, 6] to obtain a large sample approximation to this distribution. In the Appendix, we show how to obtain such an approximation. Note that from the estimation point of view, the empirical weight functionŵ(Á)
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should be chosen to have an interpretable summary D w for the treatment difference over ½t 0 , t 1 .
An empirical study
We conducted an extensive numerical study to examine the performance of the new estimation procedure, especially for cases when the event rates are low. For all cases studied, the empirical coverage levels of our interval estimators based onD w were very close to their nominal counterparts even when the crude event rates were only around 3% under various practical settings. For instance, under one of the various simulation settings, we mimicked the PEACE study with the aforementioned relatively young patient population. First, for each treatment group, we fitted the observed survival data with a two-parameter Weibull model. We then generated 1000 random samples of survival times via each fitted Weibull model with various sample sizes. Furthermore, we assumed that the censoring distribution for each treatment group is the same as the observed KM estimate. Note that the ranges of the observed KM curves for the censoring time were from 0 to 1 in both treatment groups. The empirical coverage levels of the nominal 0.95 confidence interval estimates for the integrated difference D w based onD w with various sample sizes and ½t 0 , t 1 are the entries under the heading '(4.7, 4.5)' for the average crude event rates in Table 2 . We also considered cases for which the average crude event rates of the control are about 3%, 8%, and 10% by modifying the scale parameters of the above two fitted Weibull models. The corresponding empirical coverage levels of 0.95 confidence interval estimates are also reported in Table 2 with various sample sizes and ½t 0 , t 1 . All the entries in Table 2 are practically equal to their nominal counterparts. Note that for this simulation, we let the weight function w(Á) be one.
Remarks
It is important to note that D w , the average difference of two survival curves, has a desirable feature. That is, it is an easily interpretable, model-free parameter. Moreover, its estimateD w is purely nonparametric. On the other hand, the standard hazard ratio estimate does not have a clear interpretation for the treatment contrast when the PH assumption is not valid.
If we let t 0 = 0 and w(Á) be a constant weight function, t 1 D w is the difference of the two areas under the survival curves up to t 1 . The area under the survival curve from 0 to t 1 is also called the restricted mean survival time [20, 21] . Although the large sample theory has been developed for estimators of the restricted mean, our inference procedures are for the parameter D w with a general positive weight function w(Á). In addition, we find that the resampling method proposed in this article may provide better approximations to the distributions of the estimators. The choice of ½t 0 , t 1 for the integrated differencê D w depends on the questions to be answered from the study. For example, to test equivalence of two groups under a superiority trial setting, Pepe and Fleming [5, 6] let t 0 = 0 and choose a weight function empirically to increase the power of the test. From the estimation point of view, one may choose a time interval whose members' ts are relatively large to examine a long survival benefit from the new treatment. Furthermore, one would choose the weight function w(Á) for which the resulting D w is a clinically meaningful summary measure. When the event rates are low, under an equivalence or noninferiority study setting, the interval estimate based onD w appears to be a more natural summary metric for quantifying the treatment contrast at the final or interim analysis than its PH counterpart. For this situation, we strongly recommend using D w as the primary parameter to design the trial instead of using a conventional, event-driven approach, which may require far greater resources in order to obtain a definite answer to the question regarding the treatment difference. To avoid a post hoc choice of the time interval, the ½t 0 , t 1 should be prespecified in the protocol or the statistical analysis plan.
Note that oftentimes, the numbers of events utilized at the design stage for an event-driven trial tend to be significantly higher than the observed. This may be due to the improvement of the standard care (or the control) or to publication bias for estimating the historical event rates or to the investigator's enthusiasm for convincing the sponsor to support the study. The lack of a sufficient number of observed events may cause an early termination of the study. Such conclusion of lack of information can be rather misleading. The fundamental problem of using an estimated hazard ratio as a measure of the treatment contrast is that we fail to use the underlying event rate information in designing, monitoring, and analyzing the study. On the other hand, the precision of the estimated difference of two KM curves depends on the number of study participants. Using this survival rate difference metric to quantify the treatment difference may lead us to conclude that the two treatments are 'equivalent' (not lack of information). Moreover, for the low event rate case with fixed numbers of study subjects, when the event rates decrease, the precision of the Cox's hazard ratio estimate decreases because the standard error of the hazard ratio estimate is approximately inversely related to the number of observed events, but its counterpart of the estimated integrated survival rate difference would increase. This interesting feature, coupled with its easy interpretation, makes the integrated survival rate difference a more desirable measure for the treatment contrast than its hazard ratio-based counterpart for equivalence or noninferiority studies. On the other hand, in the superiority study setting, as pointed out by a referee, the increasing precision of the estimated integrated survival rate difference does not necessarily mean increasing power for detecting the difference between the two survival curves. This is because the effect size of the integrated survival rate difference may also decrease when the number of observed events decreases.
For designing a study with the integrated difference of survival rates, one needs to choose the time interval ½t 0 , t 1 of interest, a parametric model (e.g., Weibull) to generate event times, and the patient's accrual profile over time. The sample size may be determined by specifying a desirable length of the interval estimate for the integrated difference over ½t 0 , t 1 via simulation. For choosing the time points for the interim analysis, we may use the ratio of the expected variance of the estimator for the integrated difference of the event rates at the final analysis, relative to that at the planned interim analysis as the information time. One can then use the standard efficacy stopping boundary as a guidance for interim analysis.
The computer code for implementing the inference procedures for the integrated difference of survival rates can be downloaded from http:// bcb.dfci.harvard.edu/~huno/BCB/R_code.html.
By central limit theorem, W converges weakly to a normal distribution with mean zero and variance E(t 2 1i + t 2 2i ), which can be estimated by its empirical counterpart, that is n 2 Note that when D t ð Þ = t, t 2 ½t 0 , t 1 , the second term disappears and the simple resampling method proposed in this article still provides valid inference for t as long asŵ(t) is uniformly convergent in probability to a deterministic positive function w(t):
Note that Equation (6) is a mild condition. For example, we can show that the weight function
the reciprocal of a variance estimate ofD(t), satisfies Equation (6). Specifically, first, it follows from the uniform consistency ofŜ k (Á),Ĝ k (u), andL k (u) that w(t) is a uniform consistent estimator for
Furthermore, with routine algebraic operations, we can show that w(t) À w(t) = Integrated difference of survival rates over time 577
